Structure Therapeutics Reports 12-Week Results for Obesity Drug GSBR-1290, Achieving Significant Weight Loss
Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced positive 12-week